• 1
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350: 1047-1059.
  • 2
    Reeves GK,Beral V,Green J,Gathani T,Bull D;Million Women Study Collaborators. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006; 7: 910-918.
  • 3
    Chlebowski RT,Hendrix SL,Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289: 3243-3253.
  • 4
    Campagnoli C,Clavel-Chapelon F,Kaaks R,Peris C,Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005; 96: 95-108.
  • 5
    Lee SA,Ross RK,Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer. 2005; 92: 2049-2058.
  • 6
    Li CI,Malone KE,Porter PL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev. 2008; 17: 43-50.
  • 7
    Flesch-Janys D,Slanger T,Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008; 123: 933-941.
  • 8
    Tjonneland A,Christensen J,Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer. 2004; 100: 2328-2337.
  • 9
    Fournier A,Fabre A,Mesrine S,Boutron-Ruault MC,Berrino F,Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008; 26: 1260-1268.
  • 10
    Lee S,Kolonel L,Wilkens L,Wan P,Henderson B,Pike M. Postmenopausal hormone therapy and breast cancer risk: The Multiethnic Cohort. Int J Cancer. 2006; 118: 1285-1291.
  • 11
    Brinton LA,Richesson D,Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3150-3160.
  • 12
    National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, November 2006 Submission (1973–2004)-Linked to County Attributes-Total U.S., 1969–2004 Counties. Bethesda, MD: National Cancer Institute, DCCPS Surveillance Research Program, Cancer Statistics Branch; released April 2007, based on the November 2006 submission. Available at: Accessed on February 7, 2008.
  • 13
    Calle EE,Rodriguez C,Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer. 2002; 94: 2490-2501.
  • 14
    Stellman SD,Garfinkel L. Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women. J Natl Cancer Inst. 1986; 76: 1057-1063.
  • 15
    Bergmann MM,Calle EE,Mervis CA,Miracle-McMahill HL,Thun MJ,Heath CW. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol. 1998; 147: 556-562.
  • 16
    Calle EE,Terrell DD. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol. 1993; 137: 235-241.
  • 17
    Huang Z,Hankinson S,Colditz G, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997; 278: 1407-1411.
  • 18
    Anderson GL,Limacher M,Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial. JAMA. 2004; 291: 1701-1712.
  • 19
    Rossouw JE,Anderson GL,Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
  • 20
    Althuis MD,Fergenbaum JH,Garcia-Closas M,Brinton LA,Madigan MP,Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1558-1568.
  • 21
    Jain MG,Rohan TE,Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology. 1999; 10: 260-263.